ReviewBreast cancer (Tokyo, Japan)2025

Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer.

Kazuhiro Kakimi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.